Anery Patel, Laura Graeff-Armas, Meredith Ross, Whitney Goldner

Research output: Chapter in Book/Report/Conference proceedingChapter


Hypercalcemia is a metabolic complication in some patients with malignancy, often seen in later-stage malignancies, and often predicts a poor prognosis. The most common causes include tumor secretion of parathyroid hormone-related peptide, excess production of 1, 25-dihydroxy vitamin D, and osteolytic cytokine production. However, the etiology is not always mediated by malignancy, and other causes such as PTH-mediated hypercalcemia should be considered. This chapter reviews the etiology of hypercalcemia associated with malignancy and proposed mechanisms. It also discusses appropriate evaluation and treatment strategies.

Original languageEnglish (US)
Title of host publicationAbeloff’s Clinical Oncology
ISBN (Electronic)9780323476744
StatePublished - Jan 1 2019


  • Bisphosphonates
  • Denosumab
  • Etiology
  • Hypercalcemia
  • Malignancy
  • PTHrP
  • Parathyroid hormone-related peptide
  • Treatment
  • Vitamin D

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Hypercalcemia'. Together they form a unique fingerprint.

Cite this